Immune system brakes, optical tweezers, and enzyme evolution. Three separate subjects that span this year’s Nobel Prizes in Physiology or Medicine, Physics and Chemistry. Despite the differences in theory, however, the diverse discoveries have one thing in common: they have applications in the biotechnology industry, Labiotech’s favorite subject. Releasing the immune system’s brakes in cancer […]

Tusk Therapeutics has been acquired by Swiss pharma giant Roche, which aims to develop one of its lead immunological cancer treatments. Roche has given Tusk’s shareholders €70M upfront, with up to an additional €585M planned if Tusk achieves certain milestones. Roche seems particularly interested in one of Tusk’s lead programs, an antibody that reduces the […]